1. H EALTH C ARE S ECTOR C OMPANY P RESENTATION Sarah Hemmelgarn Jason Wattier Alex Wisler Billy Wong

2. SECTOR SUMMARY SIM Weight (as of 7/31/2009) S&P 500 WeightSIM Weight+/- Consumer Discretionary 9.11%7.19%-1.92% Consumer Staples 11.81%11.65%-0.16% Energy 12.04%10.74%-1.31% Financials 13.86%8.93%-4.93% Health Care 13.73%13.30%-0.43% Industrials 9.98%12.37%2.39% Information Technology 18.72%20.41%1.69% Materials 3.40%4.98%1.58% Telecommunication Services 3.41%3.39%-0.02% Utilities 3.94%3.61%-0.34% Cash 0.00%3.38% Dividend Receivables 0.00%0.06%

3. SECTOR SUMMARY Defensive Opportunities  Aging U.S. Population  Universal health care may increase number of people insured Risks  Branded pharmaceuticals patent cliff  Lack of bargaining power under one-buyer system

4. SECTOR SUMMARY Currently underweight vs. S&P 500  SIM weight = 13.30%  S&P 500 = 13.73% Bring to even-weight with S&P500  +43 basis points

5. SECTOR SUMMARY Current SIM Holdings: Company% of SIM Current Price Target Price Div. Yield Total Upside Cardinal Health2.51%$33.84$39.182.10%18.68% Eli Lilly2.39%$33.83$37.615.60%16.79% Gilead Science0.96%$45.87$61.930.00%35.01% Johnson&Johnson4.01%$60.72$75.383.27%27.41% Wellpoint3.43%$51.90$59.480.00%15.30% *Prices as of market close 8/10/2009

6. SECTOR SUMMARY Recommended Action: CompanyUpsideAction Current Weight Target Weight Change Cardinal Health18.68%Hold2.51% 0.00% Johnson&Johnson27.41%Hold4.01% 0.00% Eli Lilly16.79%Sell2.39%0.00%- 2.39% Wellpoint15.30%Sell3.43%2.00%- 1.43% Gilead Science35.01%Buy0.96%2.50%+ 1.54% TEVA20.91%Buy0.00%2.71%+ 2.71% SECTOR TOTAL13.30%13.73%+ 0.43%

7. ELI LILLY

8. Company Overview Industry: Pharmaceuticals Founded in 1876 Develops, manufactures, and sells pharmaceutical products worldwide  Offers medicinal treatments for:  Schizophrenia, Bi-polar disorders, ADHD, Diabetes, Osteoporosis 2008 Sales: $20.378B

9. Company Overview SIM Basis = $45.61 Market Price = $33.83 Dividends = $1.92 Unrealized Holding Gain (Loss) = ($11.78) After dividends = ($9.86) Return to Date (after dividends) = -21.62%

10. Strengths & Opportunities Diversified Product Portfolio High Dividend Yield  Currently at 5.6% annual yield  Increased in each of last 42 years Aging population expected to drive demand for drugs

11. Risks & Concerns Steep upcoming patent cliff 2008 US Sales Exposed: $7,277m % of 2008 Sales Exposed: Excluding biologics 28.9% Including biologics 35.7% 2008 US Sales Exposed: $7,277m % of 2008 Sales Exposed: Excluding biologics 28.9% Including biologics 35.7%

12. Risks & Concerns Weak late-stage pipeline  Is it adequate to replace expected lost sales?  Big names to replace: Zyprexa, Cymbalta, Gemzar  Up to 35.7% of 2008 sales is exposed to generic competition through 2015  Last major drug launch: 2005  Not expecting a “steady stream of product introduction” until 2013 (Annual Report)

13. Risks & Concerns Ability to maintain current dividend payout in question  Shoring up pipeline is #1 priority  Two options:  Increased R&D spending  Purchase late-stage pipeline  R&D is costly, time consuming and risky  Acquisitions more likely due to immediate need for product introduction  Acquisitions will be priority in use of free cash  Can Eli Lilly maintain its current dividend payout?

14. Price Target Valuation target: $38.71 DCF target price: $37.24 Final target price: $37.61* Current price: $33.83 Upside potential (including dividends): 16.79% *Calculated from 75% DCF and 25% Valuation target prices Absolute Valuation HighLowMedianCurrentTarget P/Forward E24.17.116.48.2$33.65 P/S6.01.64.01.9$43.77

15. Recommendation Liquidate position in LLY Why?  Significant percentage of revenue at risk for generic competition, beginning in 2011  Concerns over relatively weak pipeline and impact on future revenue growth  Current dividend yield may not be sustainable with acquisition becoming a priority  Limited long-term upside

16. WELLPOINT

17. Headquartered in Indianapolis, Indiana Managed Healthcare Organization—Largest in the United States  Sell commercial health benefits Formed by a merger on Nov 30, 2004 by Anthem, Inc. and Wellpoint Health Networks Inc. Anthem Blue Shield and Blue Cross licensee in 14 states—brand strength

18. WELLPOINT Sector: Healthcare Industry: Managed Healthcare Current Price: $51.90 Market Cap: 24.66 Billion Current SAP Weighting: 3.43% Proposed Change: Sell 143 basis points Proposed SAP Weighting: 2.00%

19. Reasons for Selling Sales and Earnings projections low

20. Reasons for Selling Government Regulation  Government will likely pressure Managed Healthcare Companies to cut costs Profit Margins at risk due to increasing competition Rising Unemployment—has not yet peaked  More unemployment means lower commercial enrollment in healthcare plans

21. Wellpoint and Unemployment Source: Spring 2009 Healthcare Stock Presentation Obvious Negative Correlation

22. Possible Reasons Against Taking a Sell Position: Healthcare reform could actually benefit Wellpoint and other Managed Healthcare companies because more people will be in the healthcare system Wellpoint is a well diversified company that often engages in mergers and acquisitions Strong brand name with their Anthem Blue and Blue Cross brands

23. Valuation Multiple Target Price: $64.31 DCF Target Price : $58.35 Final Target Price: $59.84* Current Price: 51.90 Upside: 15.3% *Multiple Target*25%+DCF Target*75%

24. GILEAD SCIENCE

25. Gilead Science (GILD) Founded in 1987 Biopharmaceutical company that discovers, develops and commercializes therapeutics Focus on antiviral drugs for HIV/AIDS, hepatitis and influenza Recently began developing drugs for pulmonary diseases

26. Why Gilead? U.S. HIV drug market share expanding Diversifying product line Increasing R&D pipeline investment Proposed changes to health care system

27. Why Gilead? Products in pipeline  Darusentant  Elvitegravir  GS-9350  GS-9150  Aztrenam Lysine

28. Why Gilead?

29. Risks for Gilead Slowdown in HIV product sales Failure of pipeline products to gain FDA approval

30. Price Target Valuation target: $71.31 DCF target: $58.50 Final target: $61.70* Current price: $45.76 Upside potential: 34.84% *Calculated from 75% DCF and 25% Valuation target prices

31. TEVA Pharmaceuticals

32. TEVA Company – Based in Israel, largest generic drug manufacturer in the world. Investment Thesis: Company’s position as a leader in the generic market, relatively good valuation, along with very favorable macro trends for the generic drug industry, lead us to recommend purchasing 271 basis points.

33. Why TEVA? Favorable Macro Trends for Industry a) Availability of Generic Drugs as Substitutes for name-brands  Approximately 75% of all FDA-approved drugs have generic counterparts.  In 2008, 69% of all prescriptions dispensed were generics. b) Expected Growth of Generic Drug Market  $80 billion in 2008, expected to be $84 billion in 2009 and $129.3 billion in 2014 CAGR of 9% for the 5-year period  U.S.: projected $34B in 2009 and $54B in 2014 CAGR of 9.7%

34. Why TEVA? c) Cost Discrepancy  National Association of Chain Drug Stores [2007]: Average Retail Price (Brand-Name) = $119.51 Average Retail Price (Generic) = $34.34 d) Broad-based Support from Retailers  Price Competition among retailers such as CVS, Walgreen, and Rite Aid has been a big catalyst behind the greater use of generic drugs. Walmart’s $4 generic medicine offer  Generic drugs represent both lower costs and higher margins to these retailers than brand name drugs.

35. Why TEVA? d) Regulatory Favoritism  For the most part, many aspects of U.S. and international health care reforms favor generics in their attempt to curb costs.  Example – Medicare Part D’s, which accounted for 19% of all retail prescriptions in 2007, “success” is attributed in large part to its significant use of generic drugs.

36. Why TEVA? Positives: 1) Largest generic drug manufacturer in the world 2) Enjoyed a 23% sales growth through the first 6 months of 2009 despite global recession, and only had one single-digit growth year in the past 5 years. 3) Worldwide market leader and in North America, the largest generic drug market in the world, and among the leaders in Europe. 4) Has size and capacity to capitalize on the upcoming patent “cliff.”

37. Why TEVA? Worries/Risks/Concerns: 1) Increased competition among generic manufacturer and from the “names” of the industry. 2) Prevalence of Generics in the market will reduce incentive for brand-names to invest in new drugs. 3) Presence in Asia not as strong as in Europe or North America.

38. Valuation Valuation MethodTarget Per Share AmountTarget MultipleTarget Price P/Forward E3.351756.95 P/Sale15.23460.94 P/CF3.611657.76 P/Book19.913.569.67 DCF 63.01 Target Price (75%-DCF, 25%-Multiple) $62.59 Current Price $51.51 Dividend Yield 1.00% Upside 22.5%

39. Summary Recommended Action: CompanyUpsideAction Current Weight Target Weight Change Cardinal Health18.68%Hold2.51% 0.00% Johnson&Johnson27.41%Hold4.01% 0.00% Eli Lilly16.79%Sell2.39%0.00%- 2.39% Wellpoint15.30%Sell3.43%2.00%- 1.43% Gilead Science35.01%Buy0.96%2.50%+ 1.54% TEVA20.91%Buy0.00%2.71%+ 2.71% SECTOR TOTAL13.30%13.73%+ 0.43%

40. QUESTIONS?